Second treatment with rituximab in B-cell non-Hodgkin's lymphoma: efficacy and toxicity on 41 patients treated at CHU-Lyon Sud

Lemieux, Bernard; Bouafia, Fadhela; Thieblemont, Catherine; Hequet, Olivier; Arnaud, Philippe; Tartas, Sophie; Traulle, Catherine; Salles, Gilles; Coiffier, Bertrand
November 2004
Hematology Journal;2004, Vol. 5 Issue 6, p467
Academic Journal
The purpose of this study was to evaluate retrospectively the effect of a second treatment with rituximab for patients who progressed after a response to a first treatment. We analysed the charts of 41 patients treated at CHU Lyon-Sud between 1997 and May 2003. Patients were treated with rituximab alone or with a combination of rituximab and chemotherapy. The overall response rate (complete and partial response) was 73%for the second treatment. The median time to progression was longer but not significant for the second treatment in comparison with the first one (15.2 versus 11.3 months, P=0.09). The second treatment was well tolerated. Thus, a second treatment with rituximab should be considered, alone or in combination with chemotherapy, for patients who progress after a first response to rituximab.The Hematology Journal (2004) 5, 467-471. doi:10.1038/sj.thj.6200559


Related Articles

  • A model of in vivo purging with Rituximab and high-dose AraC in follicular and mantle cell lymphoma. Arcaini, L; Orlandi, E; Alessandrino, Ep; Iacona, I; Brusamolino, E; Bonfichi, M; Bernasconi, P; Calatroni, S; Tenore, A; Montanari, F; Troletti, D; Pascutto, C; Regazzi, M; Lazzarino, M // Bone Marrow Transplantation;Jul2004, Vol. 34 Issue 2, p175 

    Summary:We studied a model of in vivo purging with Rituximab and high-dose (HD) cytarabine in 14 patients with relapsed/refractory follicular lymphoma and two with refractory mantle cell lymphoma enrolled in a program of HD chemotherapy and autotransplant. After two courses of debulking...

  • Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma. Borgerding, Andrea; Hasenkamp, Justin; Glaß, Bertram; Wulf, Gerald; Trümper, Lorenz // Annals of Hematology;Mar2010, Vol. 89 Issue 3, p283 

    Neither effective salvage regimens nor the outcome and response to retherapy with rituximab containing chemotherapy have been defined for rituximab pre-treated patients with relapsing aggressive lymphoma. We report here a single-centre retrospective outcome analysis of second-line...

  • Rituximab therapy in malignant lymphoma. Coiffier, B. // Oncogene;5/28/2007, Vol. 26 Issue 25, p3603 

    Rituximab is the first monoclonal antibody to have been registered for the treatment of B-cell lymphomas. Randomized studies haves demonstrated its activity in follicular lymphoma (FL), mantle cell lymphoma and diffuse large B-cell lymphoma (DLBCL) in untreated or relapsing patients....

  • Immunothérapie des lymphomes. Reyes, F. // Oncologie;mai2006, Vol. 8 Issue 4, p331 

    Rituximab is the first monoclonal antibody to have been registered for the treatment of aggressive and indolent, untreated or relapsed B-cell lymphomas. The combination of rituximab with chemotherapy, such as R-CHOP, has the highest efficacy ever described with any chemotherapy regimen....

  • Spotlight on Rituximab in Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia1. Cvetković, Risto S.; Perry, Caroline M. // BioDrugs;2006, Vol. 20 Issue 4, p253 

    Rituximab (MabThera, Rituxan) is an anti-CD20 monoclonal antibody that induces lysis and apoptosis of normal and malignant human B cells, and sensitizes malignant B cells to the cytotoxic effect of chemotherapy. In phase III trials in patients with indolent or aggressive B-cell non-Hodgkin...

  • Acute painful lumbosacral paresthesia after intrathecal rituximab. Bromberg, J.; Doorduijn, J.; Baars, J.; Imhoff, G.; Enting, R.; Bent, M. // Journal of Neurology;Mar2012, Vol. 259 Issue 3, p559 

    The article presents a study that determines the effectiveness of rituximab in patient with recurrent aggressive B-cell lymphoma with central nervous system (CNS) localization. It outlines the method of the study in which patients were treated with rituximab without preservatives. It outlines...

  • Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. Kanungo, Anuradha; Medeiros, L. Jeffrey; Abruzzo, Lynne V.; Pei Lin // Modern Pathology;Jan2006, Vol. 19 Issue 1, p25 

    We identified 14 B-cell neoplasms with concurrent t(14;18) and chromosome 8q24 or c-MYC translocations shown by conventional cytogenetics or fluorescence in situ hybridization analysis. All cases assessed by conventional cytogenetics had a complex karyotype. There were 10 men and four women,...

  • An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. Shams'ili, Setareh; De Beukelaar, Janet; Gratama, Jan; Hooijkaas, Herbert; Van Den Bent, Martin; Van't Veer, Mars; Sillevis Smitt, Peter // Journal of Neurology;Jan2006, Vol. 253 Issue 1, p16 

    Anti-CD20 monoclonal antibody (rituximab) is effectively used in the treatment of B-cell lymphomas. Recent reports in the literature suggest that antibody associated autoimmune disorders may respond to rituximab. We therefore treated nine patients with anti-Hu or anti-Yo associated...

  • Dose dense (CEOP-14) vs dose dense and rituximab (CEOP-14+R) in high-risk diffuse large cell lymphoma. Agustin Avilés; María Nambo; Natividad Neri; Sergio Cleto; Claudia Castañeda; Judith Huerta-Guzmàn; Edgar Murillo; Margarita Contreras; Alejandra Talavera; Martha González // Medical Oncology;Jan2007, Vol. 24 Issue 1, p85 

    Abstract  To assess efficacy and toxicity of rituximab and dose chemotherapy in high-risk diffuse large cell lymphoma, we conducted a controlled clinical trial to assess efficacy and toxicity of a dose-dense regimen CEOP-14 (cyclophosphamide, epirubicin, vincristine, and prednisone every...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics